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Abstract 
Systemic inflammation is linked with development and persistence of many 
pathological pain states. Although chronic phase inflammatory responses are well reported, 
the acute phase has received limited attention. Here we investigated circulating pro-
inflammatory cytokines and C-reactive protein (CRP), and explored their relationships with 
symptom severity and other factors in acute low back pain (LBP). Ninety-nine individuals 
within two weeks of onset of acute LBP and 55 pain-free controls completed questionnaires 
related to their pain (visual analogue scale, VAS) and disability, behaviour, sleep quality and 
psychological status. CRP, interleukin-6 (IL-6), tumor necrosis factor (TNF) and interleukin-
1β (IL-1β) were measured from serum samples. Biomarkers were compared between LBP 
and control participants, and in a separate analysis, for those with “high-pain” (VAS≥4) and 
“low-pain” (VAS<4). The relationships between biomarkers and all other variables, including 
other cytokines/CRP were assessed. CRP was higher in LBP than controls and in those with 
high- than low-pain (p<0.01). IL-6 was higher in those with high- than low-pain (p<0.05), but 
not controls. Various pain and non-pain factors were associated with each biomarker 
differently. These findings suggest systemic CRP and IL-6 are important contributors to 
inflammation in the early post-onset phase of LBP and that various factors can shape these 
responses. 
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1. Introduction 
Development and persistence of many pain states has been linked with a systemic 
inflammatory response [18,117]. Attention has focused on inflammatory cytokines and 
mediators that play key roles in the immune response following injury or harmful stimuli 
[17]. Cytokines are proteins produced by numerous cells that have specific effects on the 
interactions and communications between immune-related cells, and play an integral role in 
the initiation, perpetuation and downregulation of the immune response [125]. In addition to 
their role in the immune response, pro-inflammatory cytokines sensitise nociceptors either 
directly or via stimulation of the release of agents that modulate nociception both peripherally 
and centrally [1,118]. Pro-inflammatory cytokines have also been implicated in the 
development of “sickness” symptoms such as depression, anxiety, sleep disturbances and 
cognitive deficits [70,104]. These relationships are bidirectional; peripheral pro-inflammatory 
cytokines can induce sickness behaviours and sickness behaviours can upregulate peripheral 
pro-inflammatory cytokines [69]. 
Many chronic pain conditions are linked with elevated circulating pro-inflammatory 
cytokines. Elevated tumor necrosis factor (TNF) has been reported in chronic low back pain 
(LBP) [117], interleukin-6 (IL-6) in fibromyalgia [50] and interleukin-1β (IL-1β) in chronic 
tension-type headache [29]. In some cases cytokines are related to symptom severity (e.g. 
upper-extremity overuse disorders [18]; mixed chronic musculoskeletal pain conditions [57]). 
C-reactive protein (CRP) is a reactant in the acute phases of inflammation primarily 
synthesised in the liver in response to IL-6 [48], an effect that is enhanced by IL-1β [61,64] 
and TNF [73]. Elevated CRP has been reported in pain disorders [18,87,92,121] and is also 
associated with symptom severity [18,105]. Although the role is unclear, CRP is an important 
clinical marker of inflammation [96], predictor of some inflammatory diseases [73,93], and 
marker of treatment response [65].  
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As the relationship between pro-inflammatory cytokines and pain-related 
behavioural/psychosocial symptoms is considered bidirectional, whether they develop 
simultaneously or sequential cannot be determined from cross-sectional studies of chronic 
pain. For instance, poor sleep quality and elevated IL-6 have both been reported in people 
with chronic LBP [47,66], increased IL-6 before sleep onset correlates with poorer sleep 
quality [51], and conversely, poorer sleep quality correlates with higher IL-6 during the day 
[52,113]. Further, increased IL-6 and TNF are commonly observed in both depression [30] 
and chronic pain [37,47], and depression is linked with elevated pro-inflammatory cytokines 
and reduced sleep quality [71]. Further complicating the interpretation is the influence of age, 
gender and body mass index (BMI) on cytokines [8,17,116]. 
Most studies report inflammatory profiles in individuals already in chronic pain. 
Although the role of local inflammation immediately after an injury is clear, understanding of 
the systemic inflammatory response in the acute stage of LBP is limited. Here we aimed to: i) 
evaluate systemic pro-inflammatory markers (CRP, TNF, IL-6 and IL-1β) in people within 
two weeks of onset of an episode of acute LBP and controls with no history of major LBP; ii) 
compare these markers between participants with mild and moderate-to-severe LBP; and iii) 
examine the relationships between each cytokine/CRP and demographic, behavioural and 
clinical features plus the other cytokines/CRP.  
 
2. Methods 
2.1 Participants 
Ninety-nine people in an acute episode of LBP (53 M, 46 F) aged 29±8 (mean±SD) 
years and fifty-five healthy controls (23 M, 32 F) aged 27±6 years participated in the study. 
Participants were recruited through advertisements around the university and local 
community, social media, and via a professional recruitment agency. Ethical clearance was 
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obtained from the university Medical Research Ethics Committee. All participants provided 
informed consent and procedures were conducted in accordance with the Declaration of 
Helsinki. 
LBP participants were recruited within two weeks of onset of an acute episode of LBP 
following at least one month without pain. A LBP episode was defined as pain that had lasted 
for longer than 24 hours, caused functional limitation, and caused them to seek or seriously 
consider medical or allied health intervention. Participants were excluded if they had known 
or suspected serious spinal pathology (e.g. fracture, inflammatory/infective spinal disease, 
cauda equine syndrome, metastasis and neurological disorders). Participants were also 
excluded if they were less than 18 years old, had major pain or injury to other body regions in 
the previous 12 months, or had other major diseases or disorders (e.g. chronic renal/endocrine 
disorders). To control factors that might influence inflammation, participants were excluded 
if they were using corticosteroids, anti-cytokine therapy [18], or were greater than 50 years 
old to exclude undiagnosed cardiovascular disease. Participants were allowed to use pain 
medications that do not affect cytokines (e.g. paracetamol) and if required could use non-
steroidal anti-inflammatory pain medication (e.g. Ibuprofen) provided it ceased five days 
prior to blood collection. After data collection, five participants were excluded from the 
dataset because they were identified to have a comorbidity known to influence inflammation 
(hypothyroidism [N=2], endometriosis [N=2] and reactive arthritis [N=1]). 
On arrival at the assessment session participants were asked to rate their “average” 
level of LBP over the last week using a visual analogue scale (VAS) anchored with “no pain” 
at 0 and “worst pain imaginable” at 10. Pain-related disability was also assessed using the 
Roland Morris Disability Questionnaire (RMDQ) [95], which is a self-administered 
questionnaire consisting of 24 items associated with physical functions likely to be affected 
by LBP. An item receives a score of 1 if it is applicable to the respondent or a score of 0 if it 
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is not, with a total score range of 0 (no disability) to 24 (severe disability). Potential control 
participants who reported a score >0 on the VAS and/or RMDQ were excluded from the 
study. Potential LBP participants who reported pain of <1 on the VAS and/or a score of <1 
on the RMDQ in the past week were excluded from the study.  
2.2 Categorization of participants 
Participants were categorised in two ways: 1) those with (LBP) and without LBP 
(controls), and 2) those with moderate-to-severe LBP (VAS≥4, “high-pain”), those with mild 
LBP (VAS<4, “low-pain”), and controls. The VAS cut-off used to distinguish between 
moderate-to-severe and mild LBP is based on those reported by Boonstra et al. [13]. 
2.3 Questionnaires 
Demographic and health variables: Age, gender, co-morbidities, and body mass 
index (BMI: weight [kg] divided by the squared height) were collected. Participants reported 
smoking history (current/previous smoker), alcohol habits (frequency and amount 
consumed), and whether they had experienced previous LBP (yes/no). 
Centre for Epidemiological Studies of Depression Scale (CES-D): The CES-D is a 20-
item measure of depressive symptoms in the past week. Respondents’ rate how often over the 
past week they experienced symptoms associated with depression using a four-point Likert 
scale ranging from 0 (“rarely or none of the time”) to 3 (“most or all of the time”), for an 
overall score out of 60. Scores greater than 15 identify individuals at high risk for clinical 
depression with high sensitivity and specificity [62]. Both total CES-D scores and whether 
participants were experiencing clinically significant depressive symptoms, defined as a total 
score greater than 15 [86], were considered in the analysis.   
Pain Catastrophizing Scale (PCS): The 13-item PCS is a valid and reliable measure 
of thoughts and feelings related to pain, which suggest catastrophic cognitions [76]. 
Responses to questions are quantified on a five-point Likert scale ranging from 0 (“not at 
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all”) to 4 (“all the time”) with respect to how often the respondent experiences certain 
thoughts and feelings when in pain. Components of the PCS include scores of magnification 
(“I become afraid that the pain will get worse”), rumination (“I worry all the time whether the 
pain will end”) and helplessness (“I feel I can’t go on”). Together, these components provide 
an overall score of catastrophizing, ranging from 0 to 52. Individual component and total PCS 
scores were used for analyses.  
Fear Avoidance Beliefs Questionnaire (FABQ): The FABQ assesses fearful and 
avoidant behaviours with 16 items that measure the agreement of statements related to 
physical activity (FABQ-PA: 5 items) and work (FABQ-W: 11 items) that affect the 
participant’s LBP [115]. Responses to each item are quantified on a 0 (“completely 
disagree”) to 7 (“completely agree”) scale for a maximum score of 30 and 66 for the FABQ-
PA and FABQ-W, respectively. Higher scores indicate higher levels of fear-avoidance 
beliefs, which has been validated in chronic LBP patients [43]. Unemployed participants 
were removed from the final FABQ-W dataset.  
Pain Self-Efficacy Questionnaire (PSEQ): The PSEQ is a 10-item questionnaire that 
quantifies the confidence people with pain have in performing activities while in pain [75]. 
Respondents rate how confidently they can perform a range of activities (e.g. work, 
household chores and socialising) on a seven-point Likert scale ranging from 0 (“not at all 
confident”) to 6 (“completely confident”), for an overall score ranging from 0 to 60. Higher 
scores reflect stronger self-efficacy beliefs and correlate with measures of pain-related 
disability, different coping strategies, and activity-specific self-efficacy beliefs (Self-Efficacy 
Scale) [54,109].  
Pittsburgh Sleep Quality Index (PSQI): Sleep duration and quality were assessed with 
the PSQI. The 19-item questionnaire evaluates global sleep complaints along seven 
dimensions, including subjective sleep quality, sleep duration and latency (time it takes to fall 
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asleep), and the frequency and severity of specific sleep-related complaints in the previous 
month [16]. Scores from each dimension (ranging from 0 to 3) are individually reported as 
component scores and summed to derive a sleep quality maximum score of 21; higher scores 
reflect greater sleep complaints. A PSQI score greater than 5 indicates poor sleep [16]. The 
PSQI and its psychometric properties have been validated in various populations including 
those with insomnia [7,16,19]. For analyses we used self-reported hours of actual sleep, 
individual component and global PSQI scores.  
2.4 Cytokine and CRP measurements in serum 
Approximately 8 ml of venous blood was drawn from each participant and collected 
into a Serum Separator Tube (Becton, Dickinson and Company), inverted four to five times, 
and allowed to clot for 30 min at room temperature. Samples were then centrifuged at 2,500 
rpm for 15 min and the supernatant serum was stored at -80 degrees in approximately 450 uL 
aliquots. Concentrations of CRP, TNF, IL-6 and IL-1β were determined using separate “high 
sensitive” (assay sensitivity: CRP=0.022 ng/ml, IL-6=0.110 pg/ml, IL-1β=0.14 pg/ml, 
TNF=0.191 pg/ml) enzyme-linked immunosorbent assays (ELISA, R&D Systems, 
Minneapolis, Minnesota). Absorbance was measured at 490/650 nm for IL-6, TNF and IL-1β, 
and 450/540 for CRP, using the Spark 10M (Tecan, Männedorf, Switzerland) or Paradigm 
(Beckman Coulter, Brea, California) microplate reader. Values below the sensitivity of the 
test were allocated a zero score. 
2.5 Data collection 
Participants completed all questionnaires online within 24 hours of providing a blood 
sample. Participants who were considered eligible following the evaluation phase provided 
informed consent and a blood sample. All samples were collected between 8:00 am and 6:00 
pm by research staff trained in venepuncture. Participants were instructed to refrain from 
moderate to high-level exercise for at least 24 hours before blood collection [18]. 
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2.6 Statistical analysis 
Demographic features and questionnaire data were compared between control and 
LBP groups, and between the control, low-pain (VAS<4) and high-pain (VAS≥4) groups 
using either chi-squared tests (categorical variables) or independent t-tests (continuous 
variables). As data for serum concentrations of CRP, TNF and IL-6 were skewed 
(Kolmogorov-Smirnov test: p<0.05), values were log-transformed before further analysis. 
Because over 50% of IL-1β values were allocated a zero score (concentrations below the 
accuracy of the test), no suitable transformation method achieved a normal distribution, and 
nonparametric tests (i.e. Mann-Whitney U test, Kruskal-Wallis ANOVA and quantile 
regression) were used with raw IL-1β values. Cytokine/CRP concentrations were first 
compared between LBP and controls using independent t-tests (log-transformed CRP, TNF 
and IL-6) or the Mann-Whitney U test (raw IL-1β). Univariate ANOVAs (group: 3 levels x 
cytokine/CRP) were then used to explore differences between the high-pain, low-pain and 
control groups for each cytokine or CRP. Blood collection times (24 h) were compared 
between control and LBP participants, and between high-pain and low-pain participants using 
t-tests to consider the effect of diurnal variation in biomarker levels between groups. 
Duncan’s multiple range test was used for post-hoc analysis.  
Stepwise (forward and backward selection) linear regression models were undertaken 
to investigate the relationships between each cytokine (except IL-1β) or CRP separately with 
demographic, behavioural and clinical features and the other cytokines/CRP. In the same 
manner, quantile regression was performed to calculate the association of these variables by 
quantiles (50th, 60th, 70th, 80thand 85th) of IL-1β. Quantile regression is similar to linear 
regression, but instead of estimating the mean of the dependant variable, estimates the 
median (or other specified quantile), conditional on the values of the independent variable. 
Quantile regression does not require distributional assumption and is more robust in response 
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to extreme outliers [58]. Regression analyses were also undertaken without inclusion of the 
control participants to determine the association of variables only assessed in the LBP 
participants (FABQ-PA, FABQ-W and PSEQ). Analyses were performed using Statistica v12 
(StatSoft) and Stata v14 (Stata Corp). P-values <0.05 were considered statistically significant. 
 
3. Results 
3.1 Group characteristics 
Participants with and without LBP did not differ significantly in terms of age, gender, 
BMI and current smoking status. A greater proportion of LBP participants were previous 
smokers (p=0.005) and had a greater incidence of at least one previous episode of LBP 
(p<0.001) than controls. LBP participants reported higher CES-D scores (p<0.001), higher 
total and component (magnification, rumination and helplessness) PCS scores (p<0.014), and 
less sleep hours per night (p=0.002). A greater proportion of participants with LBP were 
experiencing clinical depressive symptoms (CES-D>15, p=0.002) than controls (Table 1).  
Participants with LBP categorised as having either low-pain (VAS<4) or high-pain 
(VAS≥4) shared similar characteristics except that reported pain intensity (VAS, p<0.001), 
disability (RMDQ, p=0.036) and feelings of pain-related helplessness (PCS, p=0.048) were 
greater in the high-pain group (Table 2). 
3.2 Group comparison of serum cytokine/CRP concentrations  
 Serum cytokine/CRP concentrations for each group are shown in Fig. 1 and 2. CRP 
was higher in participants with LBP than controls (p=0.003), but there were no significant 
differences between groups for TNF (p=0.174), IL-6 (p=0.141) or IL-1β (p=0.197). As 
shown in Fig. 2, the three-group comparison of high-pain, low-pain and control participants 
revealed a main effect for group with respect to both CRP (F [2, 146] = 7.9, p<0.001) and IL-
6 (F [2, 150] = 3.2, p=0.045). CRP was higher in those with high-pain than low-pain (post-
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hoc: p=0.005) and controls (post-hoc: p=0.005), and IL-6 was higher in those with high-pain 
than low-pain (post-hoc: p=0.034), but not controls (post-hoc: p=0.114). There were no 
differences in TNF and IL-1β when the three groups were compared. Time of blood 
collection was not different between control and LBP participants (p=0.510), or between 
high-pain and low-pain participants (p=0.301). 
3.3 Relationship between each cytokine/CRP, demographic, behavioural and clinical features 
and other cytokines/CRP 
Linear and quantile regression analyses revealed significant associations between 
each biomarker and various non-pain factors (Table 3). CRP was positively associated with 
IL-6 (β=0.42, p<0.001), pain intensity (VAS: β=0.17, p=0.002) and BMI (β=0.16, p=0.02). 
TNF was positively associated with previous LBP (β=0.26, p=0.006) and BMI (β=0.19, 
p=0.037), and negatively associated with a lower frequency (less than monthly) of 
consumption of five or more alcoholic drinks (β=-0.36, p=0.006) and higher pain rumination 
scores (β=-0.20, p=0.031). Although not statistically significant, there was a tendency for 
lower TNF to be associated with more sleep hours per night (β=-0.32, p=0.066). Higher IL-6 
was associated with higher CRP (β=0.43, p<0.001) and less sleep (β=0.56, p=0.01). 
Interestingly, lower IL-6 was associated with the second highest category (7–9 drinks) 
relating to the number of alcoholic drinks typically consumed when drinking (β=-0.48, 
p=0.02). Quantile regression revealed a significant negative affect of IL-6 on the 70th (-0.16, 
p=0.010), 80th (-0.23, p<0.001) and 85th (-0.22, p<0.001) quantiles of IL-1β and a significant 
positive affect of CRP on the corresponding 80th (0.13, p=0.010) and 85th (0.19, p<0.001) 
quantiles of IL-1β. Higher levels of IL-1β (80th and 85th quantile) were also associated with 
lower pain intensity ratings (VAS: -0.07/-0.05, p<0.05) and higher pain magnification scores 
of the PCS (0.11, p<0.01). Further, the 85th quantile of IL-1β was higher in individuals who 
consumed alcohol more frequently (0.61/0.44, p<0.01) and who had a lower BMI (-0.03, 
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p=0.043). No associations were found in other quantiles of IL-1β. Separate regression 
analyses without controls did not identify associations between cytokines/CRP and variables 
specific to LBP, including the FABQ-W, FABQ-PA and PSEQ. 
 
4. Discussion 
This study has three major findings: i) CRP was elevated in acute LBP, particularly in 
those with greater pain, ii) IL-6 was elevated in participants with high-pain, and iii) factors 
other than pain explained some of the variance in cytokine/CRP levels. These data provide 
the first evidence for a relationship between systemic inflammatory markers, symptom 
severity and other features in the acute-phase of LBP. Early CRP and IL-6 responses may be 
key mediators of immune events that determine LBP outcome. 
Elevation of CRP, but not primary pro-inflammatory cytokines in acute LBP 
CRP provides a generic marker of active inflammation through its interplay with IL-6 
[48], and to a lesser extent TNF and IL-1β, all of which stimulate CRP synthesis [12,73]. 
There are several possible reasons why CRP was elevated in acute LBP without concurrent 
increases in individual cytokines. First, injury severity may explain the results. Pro-
inflammatory cytokine concentrations relate to the degree of tissue injury [44,100]. Although 
the injury may have been insufficient to stimulate specific cytokines detectably, the 
cumulative effect of cytokines may underlie detectable CRP production. Consistent with in-
vitro evidence of enhanced CRP production in response to IL-6 when combined with IL-1β 
[41,61,124], our data show CRP is positively correlated with both IL-6 and IL-1β.  
Second, the results may be explained by the time since injury. IL-6 at the injury site 
clears rapidly from circulation [20], but can accumulate in the liver where it continues to 
stimulate CRP synthesis [68]. Other work shows low systemic IL-6 levels accompanied by 
high systemic CRP levels in arthritic populations with high synovial fluid IL-6 levels 
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[9,79,106]. Further, cytokines exhibit distinct time-dependant response patterns with 
differences in times of peak expression and rates of development/recovery [80]. Failure to 
identify significant elevation of individual cytokines may be partly explained by variation in 
time since LBP onset between participants (within the 2-week window). However, the 
majority of participants presented between 10-14 days after onset limiting such time-
dependent variation in cytokine expression. 
Third, variation in individual responses to tissue injury requires consideration. 
Genetic differences (i.e. polymorphisms) can affect cytokine production in response to 
comparable triggers [10]. Some polymorphisms are cytokine specific (see [10]) whereas 
others have more global effects (i.e. enhanced/suppressed production of multiple cytokines) 
[120]. Demographic[99], physical [94,102] and psychosocial [25,28,31,70] factors can also 
shape cytokine/CRP profiles, independent of tissue injury (see below). Together these 
variations could limit identification of changes in specific cytokines, but still be detectable 
using robust generic markers of inflammation such as CRP [82].  
CRP as a contributor to inflammation  
Evidence is accumulating that CRP is not only a marker of inflammation and disease 
but also a director contributor [32-34]. CRP is proposed to exert pro-inflammatory effects via 
activation of the complement pathway [45,81], stimulating various inflammatory products 
including cytokines that sensitise peripheral nociceptors [91] and can exacerbate tissue 
damage [81]. As shown here in LBP, systemic CRP concentrations relate to pain/disease 
severity [18,85,105]. However, involvement of CRP in underlying pathological processes has 
been debated [5,123] because it has both pro- and anti-inflammatory effects [107]. These 
have been reported separately [6,82] and explained by two distinct CRP structural forms 
associated with opposite inflammatory properties [34]. Under inflammatory conditions 
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circulating (native) CRP can dissociate into a pro-inflammatory and predominantly tissue-
bound form of CRP [34,107,119]. Prevention of this dissociation has therapeutic benefit 
(inhibition of pro-inflammatory effects) in a rat model [83]. Taken together, CRP is a likely 
contributor to increased pain and the many symptoms attributable to inflammation.  
IL-6 elevated only in high-pain 
Elevated IL-6 only in the high-pain group, and no correlation with pain intensity 
suggests a non-linear relationship between these variables. For instance, physiological 
reactivity (such as pain) to IL-6 may require a threshold concentration. There are other 
examples: patients undergoing total knee replacement have a two-fold increase in serum IL-6 
levels post-surgery without linear relationship to knee pain [39]; and patients undergoing total 
hip replacement increase cerebrospinal fluid IL-6 levels post-surgery without linear 
correlation to postoperative pain [15]. Some studies of trauma or chronic pain do report 
correlation between IL-6 and symptom severity [26,42,57,103], but circulating IL-6 levels are 
likely to be much higher in these populations (e.g. chronic LBP [60,117]) than the acute LBP 
group reported here. The few studies that have examined IL-6 in acute conditions report 
similar findings to the present study. Carpe et al. [18] reported higher serum IL-6 levels in 
people with more severe upper extremity musculoskeletal disorders of <12 weeks, though 
levels were not correlated with symptoms. Rechardt et al. [88] showed that serum IL-6 (also 
IL-1β and TNF) levels were not different between controls and patients with musculoskeletal 
injuries of varying severity with symptom duration of <4 weeks. 
Possible anti-inflammatory role of IL-6 
Several aspects of our data imply that IL-6 might have an anti-inflammatory role in 
the acute phase of LBP. IL-6 is an integral pro-inflammatory driver in response to injury, 
stimulating the release of acute phase proteins, cell growth and proliferation [11,49,63,72]. 
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However, it also possesses anti-inflammatory properties, which include direct and indirect 
inhibition of IL-1β and TNF [3,11,98,108,111]. Such effects could attenuate IL-6 levels given 
TNF and IL-1β both stimulate IL-6 [67,74]. Carpe et al. [18], hypothesised that individuals 
less severely affected by musculoskeletal injuries would benefit most from the anti-
inflammatory properties of IL-6 to prevent hyper-inflammation in the early post-injury 
period. This could suppress IL-1β and TNF [11]; we found a non-significant tendency for 
reduced IL-1β in our LBP participants. On the other hand, inflammation augmented by IL-6 
may be less controlled or favour those more severely affected. 
Further evidence of an immunosuppressant function of IL-6 is provided by the 
observation that lower concentrations of IL-1β related to higher IL-6 and pain. An inverse 
relationship between systemic IL-1β/TNF and IL-6 levels has been reported in inflammatory 
diseases such as fibromyalgia and rheumatoid arthritis [59]. In addition, systemic TNF levels 
are markedly elevated in IL-6 knockout mice [4,122]. These findings concur with those 
reported during and post-exercise. Systemic elevation of muscle-derived IL-6 during 
exercise, thought to facilitate glucose metabolism [77], are accompanied by low TNF and IL-
1β levels [55,89,90,102]. As with injury, the mechanisms by which IL-6 attenuates TNF and 
IL-1β is through stimulation of IL-1-receptor antagonist and TNF receptors, and the potent 
anti-inflammatory cytokine IL-10 [11,101,108]. Taken together, we speculate that IL-6 
operates to control the extent of inflammation and that impaired regulation could have 
detrimental short- and long-term effects (e.g. hyper-inflammation or immunosuppression). 
Subtle or premature reductions in IL-6 anti-inflammatory activities could unmask other pro-
inflammatory mediators such as TNF, which are elevated in chronic LBP [116,117] and was 
associated with previous LBP in the current study. Longitudinal studies are needed. 
Relationship between cytokine/CRP levels and non-pain factors 
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Several factors other than pain were associated with concentrations of cytokines/CRP. 
Consistent with previous reports, CRP, IL-6 and TNF were higher in those with a greater 
BMI [8,24,56,78]. TNF and IL-6 are considered responsible for the dyslipidemia common in 
obesity [24]. This adds to accumulating evidences that inflammation is reciprocally linked 
with obesity [36,94]. Age was unrelated to cytokine/CRP levels when accounting for all 
biomarkers in our regression model. Although this differs from the general view 
[21,35,40,99], we only included participants below 50 years, which is younger than the 
threshold age at which inflammation is considered to be affected by the ageing process [22]. 
Alcohol is a well-known immune-modulator. Numerous studies show correlation between 
low intake and low pro-inflammatory cytokines [2,25,114]. Our results reflect these findings 
for TNF and IL-1β but not IL-6, which had the opposite effect. The later result should be 
interpreted with caution because of the low number of participants (7/154) who reported this 
drinking category. 
Associations between inflammation, sleep loss and psychological symptoms are well 
documented in a variety of conditions [14,27,28,31,38,46,70]. Although the interrelationships 
are not fully understood, abnormal hypothalamic-pituitary adrenal-axis (HPA-axis) function 
has emerged as a possible explanation [27]. Disturbance to any one of these domains can 
profoundly impact the others. Here, LBP participants reported less/poorer sleep, higher pain 
catastrophizing, more depressive symptoms and a greater proportion were considered 
significantly depressed than controls. Less sleep was associated with increased IL-6 and a 
non-significant tendency for greater TNF, consistent with sleep restriction studies. . β, 
respectively.  
Methodological considerations 
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An important limitation in this study was that blood samples were not collected at the 
same time of day for each participant. Although blood collection times were not different 
between groups, cytokine diurnal rhythms (i.e. natural ebb and flow of cytokine levels 
throughout the day) [84,97,112] may explain some variation in our data. Unlike cytokines 
however, CRP is generally reported to have minimal daytime variation and is unlikely to be 
influenced by our collection methods.    
Conclusions 
This study provides insight into the early response profiles of systemic cytokines/CRP 
in acute LBP. CRP was elevated in LBP and correlated with pain, adding to evidence of its 
role in inflammation. IL-6 was only elevated in high-pain participants but not linearly related 
with pain, and the data point to it having a possible anti-inflammatory role. Involvement of 
these immune mediators systemically in the acute-phase of LBP seem both important in 
modulating inflammation but potentially harmful if not controlled appropriately. These 
responses are likely predisposed by various demographic, behavioural and psychosocial 
factors, some of which are bi-directionally linked. Future longitudinal studies should consider 
whether early inflammatory profiles and associated factors are predictive of persistent 
inflammation and pain. 
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Table captions 
Table 1. LBP (N = 99) and control (N = 55) participant characteristics. 
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Table 2. High-pain (N = 75) and low-pain (N = 23) participant characteristics.  
 
Figure captions 
Fig. 1. Serum concentrations of biomarkers in participants with acute low back pain (LBP) 
and pain-free controls. Box-plots represent median (horizontal line), 25th and 75th percentiles 
(box), and 10th and 90th percentiles (lines outside the box). **p<0.01. IL-6 – interleukin-6; 
TNF – tumor necrosis factor; IL-1β – interleukin-1β; CRP – C-reactive protein. 
 
Fig. 2. Serum concentrations of biomarkers in acute low back pain participants divided into 
those with high-pain (VAS≥4) and low-pain (VAS<4) and control participants. Descriptions 
of the box-plots are given in Fig. 1. *p<0.05; **p<0.01. IL-6 – interleukin-6; TNF – tumor 
necrosis factor; IL-1β – interleukin-1β; CRP – C-reactive protein. 
 
 
Table 1. LBP (N = 99) and control (N = 55) participant characteristics. 
 
Control 
 
LBP 
 
Characteristic Mean (SD) Range 
 
Mean (SD) Range P-value 
Age (yrs) 26 (6) 18–46 
 
29 (8) 18–50 0.052 
Gender male (%) 42 - 
 
54 - 0.164 
BMI (kg/m2) 23.0 (4.1) 17.4–43.4 
 
24.1 (3.8) 16.6–39.2 0.100 
Current smoker (%) 1.9 - 
 
5.7 - 0.271 
Previous smoker (%) 16.7 - 
 
39.0 - 0.005** 
Previous LBP (%) 5.8 - 
 
92.6 - <0.001*** 
Sleep hours per night (h) 7.5 (1.1) 4–10 
 
6.9 (1.2) 4–10 0.002** 
Sleep qualitya 3.4 (2.2) 0–9 
 
6.3 (3.2) 1–15 <0.001*** 
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Depressive symptomsb 7.0 (5.4) 1–27 
 
12.4 (8.0) 0–36 <0.001*** 
Significant depression (%)c 7.4 - 
 
28.9 - 0.002** 
Pain catastrophizingd: 6.6 (9.3) 0–41 
 
13.0 (10.4) 0–49 <0.001*** 
Rumination 2.8 (3.7) 0–12 
 
4.4 (3.9) 0–16 0.014* 
Magnification 1.4 (2.1) 0–9 
 
3.4 (2.6) 0–12 <0.001*** 
Helplessness 2.4 (4.3) 0–23 
 
5.2 (4.9) 0–21 <0.001*** 
aScored using the 19-item Pittsburgh Sleep Quality Index. Higher scores reflect poorer sleep. 
bScored using the 20-item Epidemiological Studies of Depression Scale. Higher scores reflect 
greater depressive symptoms.  
cInterpreted from the Epidemiological Studies of Depression Scale. Scores greater than 15 
indicate clinically significant depressive symptoms. 
dScored using the 13-item Pain Catastrophizing Scale. Higher scores reflect greater pain-
related catastrophizing. Components of the questionnaire include rumination, magnification 
and helplessness. 
Significant values are in bold font (*p<0.05; **p<0.01; ***p<0.001). 
 
 
Table 2. High-pain (N = 75) and low-pain (N = 23) participant characteristics.  
 
Low-Pain 
 
High-Pain  
Characteristic Mean (SD) Range 
 
Mean (SD) Range P-value 
Age (yrs) 30 (9) 18–49 
 
29 (8) 18–50 0.754 
Gender male (%) 57 - 
 
53 - 0.743 
BMI (kg/m2) 24.1 (3.6) 16.9–31.5 
 
24.0 (3.9) 16.6–39.2 0.901 
Current smoker (%) 4.8 - 
 
6.0 - 0.835 
Previous smoker (%) 39.1 - 
 
39.0 - 0.984 
Previous LBP (%) 95.5 - 
 
91.7 - 0.554 
Pain intensitya 2.4 (0.7) 1–3 
 
5.8 (1.3) 4–9 <0.001*** 
Disability severityb 4.7 (3.3) 1–14 
 
6.9 (4.4) 1–22 0.036* 
Sleep hours per night (h) 7.1 (1.1) 5–8.5 
 
6.8 (1.2) 4–10 0.368 
Sleep qualityc 5.7 (2.8) 1–12 
 
6.4 (3.4) 1–15 0.385 
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Depressive symptomsd 13.2 (9.7) 0–36 
 
12.2 (7.5) 0–33 0.614 
Significant depression (%)e 30.4 - 
 
28.4 - 0.849 
Fear avoidance (work)f 11.5 (8.7) 0–27 
 
11.7 (9.7) 0–36 0.926 
Fear avoidance (activity)g 13.3 (5.8) 0–24 
 
15.0 (5.3) 0–24 0.191 
Pain self-efficacyh 47.7 (10.7) 14–60 
 
44.3 (11.0) 18–60 0.275 
Pain catastrophizingi: 9.9 (8.0) 2–34 
 
14.0 (10.9) 0–49 0.102 
Rumination 3.3 (3.2) 0–12 
 
4.8 (4.1) 0–16 0.123 
Magnification 3.2 (2.1) 0–9 
 
3.5 (2.8) 0–12 0.636 
Helplessness 3.4 (3.2) 0–13 
 
5.7 (5.2) 0–21 0.048* 
aScored on a 0 to 10 visual analogue scale (0 = no pain, 10 = worst pain imaginable) 
bScored using the 24-item Roland Morris Disability Questionnaire. Higher scores reflect 
greater disability. 
cScored using the 19-item Pittsburgh Sleep Quality Index. Higher scores reflect poorer sleep. 
dScored using the 20-item Epidemiological Studies of Depression Scale. Higher scores reflect 
greater depressive symptoms.  
eInterpreted from the Epidemiological Studies of Depression Scale. Scores greater than 15 
indicate clinically significant depressive symptoms. 
fScored using the 5-item Fear Avoidance Beliefs Questionnaire-Work. Higher scores indicate 
higher levels of fear-avoidance beliefs related to work. 
gScored using the 11-item Fear Avoidance Beliefs Questionnaire-Physical Activity. Higher 
scores indicate higher levels of fear-avoidance beliefs related to physical activity. 
hScored using the 10-item Pain Self-Efficacy Questionnaire. Higher scores reflect stronger 
self-efficacy beliefs with respect to performing activities while in pain.  
iScored using the 13-item Pain Catastrophizing Scale. Higher scores reflect greater pain-
related catastrophizing. Components of the questionnaire include rumination, magnification 
and helplessness. 
Significant values are in bold font (*p<0.05; **p<0.01; ***p<0.001). 
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Table 3. Association of all factors including other biomarkers on serum cytokine and CRP levels.  
Variable CRP TNF IL-6 IL-1β: 70th quantile IL-1β: 80th quantile IL-1β: 85th quantile 
CRP - - 0.43 (0.27–0.59)*** 0.10 (0.00–0.19) 0.13 (0.03–0.22)* 0.19 (0.11–0.28)*** 
IL-6 0.42 (0.28–0.57)*** - - -0.16 (-0.28–-0.04)* -0.23 (-0.34– -0.11)*** -0.22 (-0.33– -0.12)*** 
Pain intensity 0.17 (0.03–0.31)* - - -0.03 (-0.09–0.20) -0.07 (-0.12– -0.02)* -0.05 (-0.10–0.00)* 
Age - - - 0.01 (-0.01–0.02) 0.00 (-0.01–0.02) 0.00 (-0.01–0.01) 
BMI 0.16 (0.02–0.31)* 0.19 (0.01–0.36)* - 0.01 (-0.02–0.04) 0.00 (-0.03–0.03) -0.03 (-0.05–0.00)* 
Previous LBP - 0.26 (0.08–0.45)** - -0.14 (-0.45–0.16) -0.04 (-0.33–0.26) 0.08 (-0.18–0.34) 
>7 drinksa - - -0.48 (-0.91– -0.06)* 0.04 (-0.53–0.62) -0.03 (-0.58–0.52) -0.07 (-0.56–0.42) 
<monthly 5+ drinksb - -0.36 (-0.62– -0.11)** - 0.01 (-0.20–0.22) -0.08 (-0.28–0.12) -0.11 (-0.29–0.07) 
Drink freq >4 times/wc - - - 0.07 (-0.46–0.59) 0.26 (-0.25–0.76) 0.61 (0.16–1.10)** 
Drink freq 2-3 times/wc - - - 0.06 (-0.27–0.39) 0.18 (-0.14–0.50) 0.44 (0.15–0.72)** 
<5 h sleepd - - 0.56 (0.14–0.99)* -0.39 (-1.85–1.07) -0.24 (-1.64–1.16) -0.50 (-1.75–0.75) 
>6 h sleepd - -0.32 (-0.65–0.02) - -0.19 (-0.59–0.22) 0.01 (-0.38–0.39) 0.04 (-0.30–0.39) 
Pain rumination - -0.20 (-0.37– -0.02)* - 0.01 (-0.05–0.06) 0.04 (-0.01–0.10) -0.02 (-0.07–0.03) 
Pain magnification - - - 0.06 (-0.02–0.15) 0.11 (0.03–0.19)** 0.11 (0.03–0.18)** 
Overall fit (R2) 0.30 0.21 0.31 - - - 
Data represent regression coefficients (95% confidence intervals) of various factors demonstrating an association with: i) CRP, TNF and IL-6 
using step-wise linear regression models, and ii) different quantiles (those with significant factors only shown) of IL-1β using quantile 
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regression. CRP, TNF and IL-6 levels are log transformed. IL-6 – interleukin-6; TNF – tumor necrosis factor; IL-1β – interleukin-1β; CRP – C-
reactive protein. Significant values are in bold font (*p<0.05; **p<0.01; ***p<0.001). 
aRefers to the number of alcoholic drinks typically consumed when drinking. 
bRefers to the frequency at which 5 or more alcoholic drinks are consumed in a single drinking session. 
cRefers to the frequency at which alcohol is consumed 
dRefers to the average number of hours slept per night over the past week. 
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• Findings point to circulating IL-6 and CRP as mediators of inflammation following an acute 
episode of low back pain 
• Physiological reactivity (such as pain) to IL-6 may require a threshold concentration 
• Demographic, behavioural and psychosocial factors have a likely role in shaping these acute 
inflammatory responses 
• Data differ from those in chronic LBP and provide a basis to study changes in inflammatory 
profiles in the transition from acute to persistent back pain 
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